Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 2
2006 1
2008 1
2009 5
2010 1
2013 2
2014 1
2015 1
2018 2
2019 1
2020 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic dendritic cell-based cancer vaccines: the state of the art.
Strioga MM, Felzmann T, Powell DJ Jr, Ostapenko V, Dobrovolskiene NT, Matuskova M, Michalek J, Schijns VE. Strioga MM, et al. Among authors: felzmann t. Crit Rev Immunol. 2013;33(6):489-547. doi: 10.1615/critrevimmunol.2013008033. Crit Rev Immunol. 2013. PMID: 24266347 Review.
MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy.
Heugenhauser J, Galijasevic M, Mangesius S, Goebel G, Buchroithner J, Erhart F, Pichler J, Widhalm G, Stockhammer G, Iglseder S, Freyschlag CF, Oberndorfer S, Bordihn K, von Campe G, Czech T, Surböck B, Urbanic Purkart T, Marosi C, Felzmann T, Nowosielski M. Heugenhauser J, et al. Among authors: felzmann t. Cancers (Basel). 2022 Mar 20;14(6):1579. doi: 10.3390/cancers14061579. Cancers (Basel). 2022. PMID: 35326730 Free PMC article.
Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors.
Erhart F, Hackl M, Hahne H, Buchroithner J, Meng C, Klingenbrunner S, Reitermaier R, Fischhuber K, Skalicky S, Berger W, Spiegl-Kreinecker S, Lötsch D, Ricken G, Kuster B, Wöhrer A, Widhalm G, Hainfellner J, Felzmann T, Dohnal AM, Marosi C, Visus C. Erhart F, et al. Among authors: felzmann t. NPJ Vaccines. 2020 Jan 16;5(1):5. doi: 10.1038/s41541-019-0149-x. eCollection 2020. NPJ Vaccines. 2020. PMID: 31969991 Free PMC article.
The MAPK-Activated Kinase MK2 Attenuates Dendritic Cell-Mediated Th1 Differentiation and Autoimmune Encephalomyelitis.
Soukup K, Halfmann A, Le Bras M, Sahin E, Vittori S, Poyer F, Schuh C, Luger R, Niederreiter B, Haider T, Stoiber D, Blüml S, Schabbauer G, Kotlyarov A, Gaestel M, Felzmann T, Dohnal AM. Soukup K, et al. Among authors: felzmann t. J Immunol. 2015 Jul 15;195(2):541-52. doi: 10.4049/jimmunol.1401663. Epub 2015 Jun 15. J Immunol. 2015. PMID: 26078274
Spheroid glioblastoma culture conditions as antigen source for dendritic cell-based immunotherapy: spheroid proteins are survival-relevant targets but can impair immunogenic interferon γ production.
Erhart F, Weiss T, Klingenbrunner S, Fischhuber K, Reitermaier R, Halfmann A, Blauensteiner B, Lötsch D, Spiegl-Kreinecker S, Berger W, Sialana FJ, Lubec G, Felzmann T, Dohnal A, Visus C. Erhart F, et al. Among authors: felzmann t. Cytotherapy. 2019 Jun;21(6):643-658. doi: 10.1016/j.jcyt.2019.03.002. Epub 2019 Apr 8. Cytotherapy. 2019. PMID: 30975602
Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.
Erhart F, Buchroithner J, Reitermaier R, Fischhuber K, Klingenbrunner S, Sloma I, Hibsh D, Kozol R, Efroni S, Ricken G, Wöhrer A, Haberler C, Hainfellner J, Krumpl G, Felzmann T, Dohnal AM, Marosi C, Visus C. Erhart F, et al. Among authors: felzmann t. Acta Neuropathol Commun. 2018 Dec 5;6(1):135. doi: 10.1186/s40478-018-0621-2. Acta Neuropathol Commun. 2018. PMID: 30518425 Free PMC article. Clinical Trial.
Vascular endothelia growth factor targeted therapy may improve the effect of dendritic cell-based cancer immune therapy.
Buchroithner J, Pichler J, Marosi C, Widhalm G, Seiz-Rosenhagen M, Novosielski M, Oberndorfer S, Ruckser R, Rössler K, Azizi A, von Campe G, Bordihn K, Felzmann T. Buchroithner J, et al. Among authors: felzmann t. Int J Clin Pharmacol Ther. 2014 Jan;52(1):76-7. doi: 10.5414/CPXCES13EA02. Int J Clin Pharmacol Ther. 2014. PMID: 24321210 Clinical Trial. No abstract available.
Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial.
Buchroithner J, Erhart F, Pichler J, Widhalm G, Preusser M, Stockhammer G, Nowosielski M, Iglseder S, Freyschlag CF, Oberndorfer S, Bordihn K, von Campe G, Hoffermann M, Ruckser R, Rössler K, Spiegl-Kreinecker S, Fischer MB, Czech T, Visus C, Krumpl G, Felzmann T, Marosi C. Buchroithner J, et al. Among authors: felzmann t. Cancers (Basel). 2018 Oct 5;10(10):372. doi: 10.3390/cancers10100372. Cancers (Basel). 2018. PMID: 30301187 Free PMC article.
19 results